Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: A prospective randomized study

American Journal of Gastroenterology

Volumn 95, Issue 1, 2000, Pages 218-222

  Liu, Chi Leung ^a   Fan, Sheung Tat ^a   Ng, Irene Oi Lin ^a   Lo, Chung Mau ^a   Poon, Ronnie Tung Ping ^a   Wong, John ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SINGLE-BLIND METHOD; SURVIVAL RATE; TAMOXIFEN;

EID: 0033988010     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(99)00747-9     Document Type: Article

References (24)

1. Okuda K., Fujimoto I., Hanai A., et al. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res. 47:1987;4967-4972.
2. Primary liver cancer in Japan. Cancer. 60:1987;1400-1411.
3. Sumi C., Yokoro K., Matsushima R. Induction of hepatic tumors by diethylstilbestrol alone or in synergism with N-nitrosobutylurea in castrated male WF rats. J Natl Cancer Inst. 70:1983;937-942.
4. Yager J.D. Jr, Yager R. Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res. 40:1980;3680-3685.
5. Shar S.R., Kew M.C. Oral contraceptives and hepatocellular carcinoma. Cancer. 49:1982;407-410.
6. Friedman M.A., Demanes D.J., Hoffman P.G. Jr. Hepatomas Hormone receptors and therapy . Am J Med. 73:1982;362-366.
7. Engstrom P.F., Levin B., Moertel C.G., et al. A phase II trial of tamoxifen in hepatocellular carcinoma. Cancer. 65:1990;2641-2643.
8. Farinati F., De-Maria N., Fornasiero A., et al. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis Sci. 37:1992;659-662.
9. Martinez Cerezo F.J., Tomas A., Donoso L., et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol. 20:1994;702-706.
10. Castells A., Bruix J., Bru C., et al. Treatment of hepatocellular carcinoma with tamoxifen A double-blind placebo-controlled trial in 120 patients . Gastroenterology. 109:1995;917-922.
11. Purposes and principles of staging. Beahrs O.H., Henson D.E., Hutter R.V.P., et al. Manual for staging of cancer. 3rd ed. 1988;3-10 J.B. Lippincott, Philadelphia.
12. Pugh R.N.H., Murray-Lyon I.M., Dawson J.L., et al. Transection of the oesophagus for bleeding varices. Br J Surg. 60:1973;646-649.
13. Sobin L.H., Wittekind C.H. TNM classification of malignant tumours. 1997;Wiley-Liss, New York.
14. Okuda K., Ohtsuki T., Obata H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 56:1985;918-928.
15. Miller S.P., Brenner S., Horton J., et al. Comparative evaluation of combined radiation-chlorambucil treatment of ovarian carcinomatosis. Cancer. 36:1975;1625-1630.
16. Elba S., Giannuzzi V., Misciagna G., et al. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroenterol. 26:1994;66-68.
17. Simonetti R.G., Liberati A., Angiolini C., et al. Treatment of hepatocellular carcinoma A systemic review of randomized controlled trials . Ann Oncol. 8:1997;117-136.
18. Tamoxifen in treatment of hepatocellular carcinoma A randomized controlled trial . Lancet. 352:1998;17-20.
19. Lai C.L., Wu P.C., Chan G.C., et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. 62:1988;479-483.
20. Boix L., Bruix J., Castells A., et al. Sex hormone receptors in hepatocellular carcinoma Is there a rationale for hormonal treatment? J Hepatol. 17:1993;187-191.
21. Nagasue N., Kohno H., Chang Y.C., et al. Clinicopathologic comparisions between estrogen receptor-positive and -negative hepatocellular carcinoma. Ann Surg. 212:1990;150-154.
22. Nagasue N., Yu L., Yukaya H., et al. Androgen and oestrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma Impact on intrahepatic recurrence after hepatic resection . Br J Surg. 82:1995;542-547.
23. Ng I.O.L., Ng M., Fan S.T. Better survival in women with resected hepatocellular carcinoma is not related to tumor proliferation or expression of hormone receptors. Am J Gastroenterol. 92:1997;1355-1358.
24. Villa E., Camellini L., Dugani A., et al. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res. 55:1995;498-500.